Research Study

Blinatumomab for Minimal Residual Disease (MRD) in Pre-B Cell Acute Lymphoblastic Leukemia Patients Following Hematopoietic Cell Transplantation: A Canadian, Multicentre Trial
Principal Investigator 
David Sanford

Overview

Body Locations and Systems 
Leukemia
ClinicalTrials.gov# 
NCT04044560
Status 
Recruiting
Study Start/End 
Jun 1, 2019 to Jun 30, 2029
Locations 
Vancouver General Hospital
Name/Title 
Edward Wong, Research Coordinator
Purpose of Study 

The purpose of this study is to determine whether treatment with Blinatumomab is effective in reducing the risk of acute lymphoblastic leukemia returning in patients with residual cancer cells remaining in the body after stem cell transplant. 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.